Lv3
210 积分 2022-05-17 加入
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
1天前
待确认
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
2天前
已完结
Targeting the Hippo pathway in cancer
8天前
已完结
CRISPR screens reveal YAP/TEAD axis as a mediator of drug-tolerant cells in EGFR-mutant NSCLC
9天前
已完结
Therapeutic targeting of TEAD transcription factors in cancer
9天前
已完结
Compound Danshen Dripping Pill effectively alleviates cGAS-STING-triggered diseases by disrupting STING-TBK1 interaction
2个月前
已完结
The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-β-mediated antiviral activity in vitro and in vivo
2个月前
已完结
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis
2个月前
已完结
CS12192, a novel JAK3/JAK1/TBK1 inhibitor, attenuates autoimmune dermatoses in murine models
2个月前
已完结
TBK1 pharmacological inhibition mitigates osteoarthritis through attenuating inflammation and cellular senescence in chondrocytes
2个月前
已完结
皖公网安备34019202002308
